CANCER RESEARCH AND BIOTECHNOLOGY AG

Investment Opportunity -

HEALING THE DISEASE THAT CAUSES CANCER

CANCER RESEARCH
AND BIOTECHNOLOGY AG

WHO ARE WE?

Cancer Research and Biotechnology AG (CRB) is a Swiss preclinical-stage oncology company focusing on mitochondrial healing.

We develop small-molecule drugs to reverse the carcinogenic mitochondrial dysfunctions that cause mutations and cancer.

We have a clear vision and a tactical roadmap with an accelerated path to first human use in fatal untreatable cancers.

The Innovation & Invitation

CANCER RESEARCH
AND BIOTECHNOLOGY AG

Today, cancer treatments are based on killing or removing cancer cells. Cancer drugs are known to be highly toxic and carcinogenic, with severe side effects..

We have been able to reduce human cancer cell viability by an innovative non-toxic drug candidate. Cancer cell proliferation was reduced in three studies conducted by an independent research laboratory in the UK with CRB's innovative drug candidate CRB091. The targeted cancers are pancreatic cancer, colorectal cancer, and triple-negative breast cancer.

The CRB innovation is based on Reverse Carcinogenesis, a patent-pending proprietary method to re-establish cells' normal mitochondrial protection against mutagenesis, thus limiting the division of cancer cells and finally starving the tumor.

We have an expedited roadmap to make this innovative drug available for humans and we are inviting investors to join our journey.



THE CORE OF OUR INNOVATION

What is the fundamental difference between our treatment and conventional treatments for the disease that causes cancer?

What is cancer and how we can cure it?

CANCER RESEARCH AND BIOTECHNOLOGY AG

1. What is cancer?

Cancer is a long process, developing from birth to end of life, and eventually, it will lead to tumors. Cancer is not the same as a tumor. Instead, a tumor is caused by cancer.

2. What causes cancer?

Cancer is caused by the environmental harmful burden that accumulates in our cells over time, leading to mitochondrial dysfunctions and oxidative stress.

3. Can cancer be healed?

Cancer can be controlled but currently not healed. However, there are many real-life cases where the disease has naturally given up completely regardless of medical interventions.

CRB has identified a uniquely specific non-genotoxic carcinogenic poison – a xenobiotic - known to act on multiple cancer hallmark targets. It accumulates in certain tissues over a lifetime. This xenobiotic is recognized as a causative agent in triggering multiple cancer-promoting mechanisms, but only in synergy with physical or chemical carcinogens.

Backed by our scientific studies, we are able to reverse cancer cell proliferation by affecting the metabolic root causes of carcinogenic mutations.

OUR FOCUS IS ON CANCER CURE vs. PRESENT DESTRUCTIVE TREATMENTS

CANCER RESEARCH AND BIOTECHNOLOGY AG

EXISTING CANCER TREATMENTS

Today, cancer cell treatments are destructive, ie. they kill body's own cells. This leads to adverse effects.

For example:

- Radiation therapy causes deadly mutations
- Chemotherapy poisons by toxins
- Immunotherapy turns body's defense system against own cells, causing treatment resistant cells

CRB'S SOLUTION

CRB's solution prevent proliferation of malignant cells, or can cure cancer, by:

- Reversing mitochondrial cancer initiation and progression in a cell
- Reviving the natural epigenetic defense and repair mechanisms in a cell
- Impeding formation of cancer by reversing carcinogenesis

In short - We are reversing cancer instead of poisoning it.

THE ACCELERATED DEVELOPMENT PATH

Why we will be able to move things forward faster that conventional drugs?

RAPID **LOW-RISK PATH** TO FIRST-IN-HUMAN

CANCER RESEARCH AND BIOTECHNOLOGY AG

SIMPLE METHOD

- CRB's way to reverse oncogenesis is relatively simple; aiming to return normal cellular (epigenetic and and immunological) disease prevention rather than trying to kill tumor cells
- The mode of action is not cell destructive or cytotoxic, but to **return the failed protection and repair against cellular mutations**
- When new cells develop without interference to their genetic error defense, tumor development will stop

Since our solution aims to heal rather than destroy cells, fast regulatory pathways are offered by authorities such as the EU EMA and the US FDA.

Best-case-scenario, CRB's solution could eventually heal the disease that causes cancer

COMPATIBILITY WITH EXISTING TREATMENTS

- CRB's innovation **does not interfere with conventional acute treatments** that aim to remove or kill tumors
- Rather, the innovation helps the cancer patient to **avoid further cell mutations developing into new cancer cells (local and systemic)**
- This will slow or stop the disease progression (e.g., give surgeons time to prevent a brain metastasis in triple neg breast cancer - such gliomas have median 5-month survival time)

PATH TO FIRST IN HUMAN – CRB COULD DISRUPT ONCOLOGY

CANCER RESEARCH AND BIOTECHNOLOGY AG

Under defined conditions, new drug development can be accelerated by alternative regulatory pathways as allowed and promoted by the authorities. **This can cut the development time and budget into a fraction.**

The conditions include low toxicity of the new drug, an unmet medical need, a hard-to-treat disease or an orphan disease, social impact and the seriousness of the disease, including secondary impacts.

CRB's solution will be disruptive in all the required conditions:

- Low toxicity shown by research and tolerability data (and preclinical studies)
- First targeted diseases are deadly cancers: pancreas, liver, and breast cancer
- Orphan & rare diseases can be included (unlike in big pharma scale)
- Social impact will be enormous due to the drug's safety profile, low cost, and fast patient reach, with a cost of a fraction of today's cancer therapies
- Global economical and human impact due to an inexpensive cancer treatment. It can quickly cover the developing economies (which typically recognize EU or US approvals)

Scheduled roadmap from today to first in human and asset acquisition can be as low as 18 months

BUSINESS POTENTIAL

How can you evaluated the potential of a new drug healing the disease that causes cancer?

Things to consider about the investment opportunity

CANCER RESEARCH AND BIOTECHNOLOGY AG

INVESTMENT SCOPE

We are looking for a 500 k€ convertible loan with minimum ticket size of 50 k€ from angel investors and offering 8% interest and 20% discount in the Series A round.
Compared to similar investment rounds (see next slide) our final funding requirements are modest.

ACCELERATED PATH

Due to previously explained factors, we are looking at an accelerated development path into an FDA approved investigational new drug. We can offer investors faster time-to money, first-in-human as little as 18 months.

EXIT POTENTIAL

We can provide investors an immense business opportunity being able to heal the disease that causes one of the most lethal diseases of humankind.

This is the last chance for angel investors to seize this opportunity.

FUNDING REFERENCES FROM ONCOLOGY

CANCER RESEARCH AND BIOTECHNOLOGY AG

COMPANY	STAGE	FUNDING (M$)	DESCRIPTION
PHOSPLATIN THERAPEUTICS	Series A	37	Phosplatin Therapeutiscs has a global license to phosphaplatins. Novel agents are in clinical development for the treatment solid tumors and hematological cancers. The lead agent is the subject of two approved IND applications.
everIMMUNE	Series A	5.7	Everimmune focuses on the development of projects in the field of microbiome oncology. Company provides a series of live biotherapeutic products (LBP), used as oral adjuvants to anticancer immunotherapies.
BIOSAPIEN	Seed	1.8	BioSapien is a pre-clinical biotech company developing novel biodegradable implantable products that deliver active pharmaceutical ingredients (APIs) for oncology indications with reduced systemic side effects.
REPLICATE	Series A	40	Replicate creates novel oncology treatments to prevent and reverse drug resistance through a self-replicating RNA platform called SynRGY.
macomics	Seed	3	Macomics focus on the development of novel, first-in-class immunotherapies designed to modulate macrophages, increasing the body's immune defence against tumours.
InceptorBio	Seed	26	InceptorBio develops cell therapy solutions to cure difficult-to-treat cancers, with a focus on novel mechanisms to improve immune cell performance in the tumor microenvironment.
Rgenta	Seed	18	Rgenta's proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glue to modulate the interactions among the spliceosome, regulatory proteins, and RNAs.
FLARE THERAPEUTICS	Series A	82	Flare Therapeutics has uncovered 'switch sites,' druggable regions that are key targets for transcription factor regulation to address mutations that cause cancer.
BLOSSOMHILL THERAPEUTICS, INC.	Series A	71	BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders.
Nirogy THERAPEUTICS	Series A	16.5	Nirogy therapeutics develops novel small molecules to target cellular transporters. Currently advances a class of small molecules intended to disrupt metabolic and immune mechanisms operative in the tumor microenvironment.

INVESTMENT OPPORTUNITY & OUR ROADMAP FORWARD

Accelerated preclinical stage – roadmap forward

CANCER RESEARCH AND BIOTECHNOLOGY AG

Under certain conditions drug development can be accelerated by following expedited regulatory pathways.
With this scenario we are looking at the following timeline and roadmap with our investors.



Typical development timeline of 10 years



SCOPE BENCHMARKS FOR POTENTIAL ACQUISITION

CANCER RESEARCH AND BIOTECHNOLOGY AG

ACQUIRED COMPANY	ACQUIROR	PRICE (M$)	DATE	EVENTS BEFORE...	DESCRIPTION OF ACQUIRED COMPANY
X-BODY BIOSCIENCES	JUNO THERAPEUTICS	44	06.02.2015	Venture round with $2.7M raised in 02/2013	X-body discovers and develops compounds against targets in oncology and ophthalmology.
AviaraD MOLECULAR MEDICINE	BIOMÉRIEUX	60	09.11.2008	Series D round with $8M raised in 01/2008	AviaraD discovers, develops, and commercializes new molecular diagnostic tests in oncology.
trapelo	NEO GENOMICS	65	03.24.2021	Venture round with $4.2M raised in 11/2017	Trapelo focuses on precision oncology.
kolltan Pharmaceuticals, Inc.	Celldex therapeutics	235	11.01.2016	Series D round with $60M raised in 03/2014	Kolltan develops new-generation monoclonal antibody oncology therapeutics.
POTENZA therapeutics	astellas	405	12.14.2018	Venture round with $5M raised in 12/2017	Potenza focuses on building a portfolio of oncology programs.
RIGONTEC	MERCK	465	09.06.2017	Series A round with $15M raised in 09/2016	RIG-I targeting RNA therapeutics developing novel immuno-oncology treatment.
Stemline	MENARINI	677	06.10.2020	Venture round with $740k raised in 01/2012	Stemline develops oncology compounds that target cancer stem cells.
VELOSBIO	MERCK	2 800	11.05.2020	Series B round with $58M raised in 10/2018	Stemline develops novel antibody-drug conjugates to treat haematological cancers.
PRINCIPIA BIOPHARMA	SANOFI	3 680	08.17.2020	Venture round with $50M raised in 08/2018	Principia focuses on oral therapies to unmet medical needs in immunology & oncology.
LOXO	Lilly	8 000	01.07.2019	Series B round with $24M raised in 05/2014	Loxo Oncology focuses on targeted cancer therapies for genetically-defined patients.

INTRODUCING

CANCER RESEARCH AND BIOTECHNOLOGY AG

Advisory Board (to be announced)

Experts in Life Sciences and Business (Prof., PhD)

Board of Directors

Kai Karttunen, Co-founder (Chair)
Kari Sarvanto, CEO and Founder

Team

CEO and Founder, Kari Sarvanto
Head of Development, Davide Guggi, PhD
Head of Research, Jenny Worthington, PhD
Director of Studies, Callum O'Kane, PhD
Clinical Lead, Delphine Remmy, PhD
Senior Scientist, Oncology, Eugenio Gaudio, PhD
Senior Scientist, Biology, Sarah Haddad, PhD
Chief Financial Officer, Sam McQuade
Regulatory Manager, US, Ingrid Fricks, PhD
Regulatory Manager, EU, Pekka Lukkari, PhD

Zug, Switzerland

1) Science team members part time

CANCER RESEARCH AND BIOTECHNOLOGY AG

CANCER RESEARCH
AND BIOTECHNOLOGY AG

CLEAR VISION
CRB's team has a clear intention to reverse carcinogenesis, and a tactical roadmap in execution with an accelerated regulatory path to reach first human use in cancer fast.

DECADES OF RESEARCH
Profound discovery of causes of mitochondrial dysfunctions and a wide base of evidence distilled from existing research data.

INNOVATIVE APPROACH
Platform innovation for novel treatments related to metabolism and mitochondria. First targeting hard-to-treat deadly cancers, fastest to patient.

REVERSE CARCINOGENESIS
First-in-class: Reverse Carcinogenesis - reviving the body's innate immune system to fight mutations that cause carcinogenesis.

FIRST HUMAN USE
Visible path to first-in-human: Preclinical studies show efficacy in human pancreatic cancer, triple-negative breast cancer and colon cancer.

MECHANISM OF ACTION
Simple mechanism of action with upstream effect on carcinogenic mutations, reviving mitochondrial repair and control mechanisms.

DRUG DE-RISKED
Drug candidates are based on well-researched mechanisms. The pharmaceutical ingredients are already shown well-tolerated, development to follow expedited FDA regulatory pathways.

CANCER RESEARCH

AND BIOTECHNOLOGY AG

Investor Presentation to be held
1.3.2023 at 14:00 in Helsinki
RSVP - Click here
For questions, please click here